Compare Abercrombie & Fitch Co. (ANF) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abercrombie & Fitch Co. vs Nuwellis Inc — how do they compare? Abercrombie & Fitch Co. trades at $92.43 (market cap $4.14B), while Nuwellis Inc trades at $3.11 (market cap $1.10M). The key difference: Abercrombie & Fitch Co. is far larger — about 3763.6× Nuwellis Inc's market cap, and Abercrombie & Fitch Co. is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| ANF | NUWE | |
|---|---|---|
Market Cap | $4.14B | $1.10M |
Sector | Consumer Cyclical | Technology |
52-Week High | $129.85 | $558.26 |
52-Week Low | $65.61 | $2.87 |
Enterprise Value | $4.81B | -$713.47K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abercrombie & Fitch (ANF) trades at $93.07, up 4.29% with strong fundamental metrics including a P/E of 9 and net income margin of 9.34%. The stock shows consistent earnings beats in recent quarters and maintains robust profitability with ROE at 39.04%. Technical indicators are neutral overall, with bullish moving averages and key resistance at $94. Recent expansion initiatives include APAC growth opportunities and partnerships with Target for back-to-college merchandise.
ANF presents a compelling value opportunity with attractive valuation multiples and strong operational performance. Upside potential exists to the $107.71 consensus price target, though risks include moderating sales growth and international market volatility. The company's disciplined expansion and brand revitalization support long-term growth prospects.
NUWE trades at $3.04, up 5.56% today, but faces bearish technical signals with oversold RSI readings. The company reported a net loss of $17.52M in 2025 with negative margins, though recent earnings beat expectations in two of the last three quarters. A reverse stock split was executed in June 2026, and new CEO Mike McCormick is focusing on pediatric market expansion.
Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and recent FDA engagement offer potential growth. Risks include financial sustainability and competitive pressures. Analyst sentiment is split evenly between Buy and Hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
